Quoin Pharmaceuticals, Ltd. (QNRX) — 8-K Filings

8-K Filings (38)

• Quoin Pharma Files 8-K on Financial Results & Operations — Mar 26, 2026
  Quoin Pharmaceuticals, Ltd. filed an 8-K on March 26, 2026, reporting under Item 2.02, "Results of Operations and Financial Condition," and Item 9.01, "Financia
• Quoin Pharma Files 8-K on Officer/Director Changes — Nov 17, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on November 17, 2025, reporting events as of November 14, 2025. The filing covers the departure of directors or certain
• 8-K Filing — Nov 12, 2025
• Quoin Pharmaceuticals Files 8-K — Oct 21, 2025 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on October 21, 2025, reporting on various events including financial statements and exhibits. The company, formerly kno
• Quoin Pharmaceuticals Files 8-K with Material Agreements — Oct 15, 2025 Risk: medium
  On October 10, 2025, Quoin Pharmaceuticals, Ltd. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securitie
• Quoin Pharmaceuticals Reports Director/Officer Changes & Financials — Aug 27, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on August 27, 2025, reporting events as of August 21, 2025. The filing pertains to the departure of directors or certai
• Quoin Pharmaceuticals Files 8-K with Key Corporate Updates — Aug 21, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on August 21, 2025, reporting on events as of August 15, 2025. The filing covers material modifications to security hol
• Quoin Pharmaceuticals Files 8-K on Financials — Aug 7, 2025 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on August 7, 2025, reporting on its Results of Operations and Financial Condition, and including Financial Statements a
• Quoin Pharmaceuticals Appoints New CEO and Directors — Jul 8, 2025 Risk: medium
  On July 3, 2025, Quoin Pharmaceuticals, Ltd. announced changes in its board of directors and executive officers. The company elected two new directors, Dr. Yoss
• Quoin Pharmaceuticals Files 8-K for Other Events — Jun 25, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on June 25, 2025, reporting an "Other Events" item as of June 24, 2025. The filing does not contain specific details ab
• Quoin Pharmaceuticals Files 8-K for Undisclosed Event — Jun 20, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on June 20, 2025, reporting an "Other Event" that occurred on June 18, 2025. The filing does not provide specific detai
• Quoin Pharmaceuticals Reports Director & Officer Changes — Jun 4, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on June 4, 2025, reporting changes effective May 29, 2025. The filing covers the departure of directors or certain offi
• Quoin Pharmaceuticals Files 8-K — May 23, 2025 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on May 23, 2025, reporting on events that occurred on May 22, 2025. The filing includes financial statements and exhibi
• Quoin Pharmaceuticals Files 8-K — May 21, 2025 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on May 21, 2025, reporting other events and financial statements and exhibits as of May 20, 2025. The company, formerly
• Quoin Pharmaceuticals Files 8-K on Financials — May 14, 2025 Risk: low
  Quoin Pharmaceuticals Ltd. filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition as of May 13, 2025. The company, formerl
• Quoin Pharmaceuticals Relocates Executive Offices — Apr 30, 2025 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on April 30, 2025, reporting other events as of April 29, 2025. The filing indicates a change in the company's principa
• Quoin Pharmaceuticals Files 8-K on Security Holder Rights — Apr 4, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on April 4, 2025, reporting material modifications to the rights of its security holders. The company, formerly known a
• Quoin Pharmaceuticals Relocates Executive Offices — Apr 2, 2025 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on April 2, 2025, reporting "Other Events." The filing indicates a change in the company's principal executive offices
• Quoin Pharmaceuticals Reports Accountant Change and Filings — Mar 20, 2025 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on March 20, 2025, reporting changes in its certifying accountant and filing financial statements and exhibits. The rep
• Quoin Pharmaceuticals Files 8-K on Financials — Mar 13, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on March 13, 2025, reporting on its Results of Operations and Financial Condition. The company, formerly known as Celle
• Quoin Pharmaceuticals Files 8-K — Feb 27, 2025 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on February 27, 2025, reporting other events. The company, formerly known as Cellect Biotechnology Ltd. and Cellect Bio
• Quoin Pharmaceuticals Files 8-K — Feb 4, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on February 4, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these e
• Quoin Pharmaceuticals Files 8-K — Jan 23, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on January 23, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these e
• Quoin Pharmaceuticals to Acquire 03 Life Sciences — Jan 16, 2025 Risk: medium
  Quoin Pharmaceuticals, Ltd. announced on January 14, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of 03 Life Sciences
• Quoin Pharmaceuticals Files 8-K — Jan 6, 2025 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on January 6, 2025, reporting other events. The company, formerly known as Cellect Biotechnology Ltd. and Cellect Biome
• Quoin Pharmaceuticals Enters Material Definitive Agreement — Dec 26, 2024 Risk: medium
  Quoin Pharmaceuticals, Ltd. announced on December 20, 2024, that it entered into a material definitive agreement. The filing also includes financial statements
• Quoin Pharmaceuticals Files 8-K: Other Event — Dec 19, 2024 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on December 19, 2024, reporting an "Other Event." The filing does not contain specific details about the event, its fin
• Quoin Pharmaceuticals Files 8-K on Corporate Events — Dec 10, 2024 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on December 10, 2024, reporting on events that occurred on December 5, 2024. The filing covers material modifications t
• Quoin Pharmaceuticals Files 8-K on Financials — Nov 8, 2024 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on November 8, 2024, reporting on its results of operations and financial condition as of November 7, 2024. The filing
• Quoin Pharmaceuticals Faces Delisting Concerns — Oct 31, 2024 Risk: high
  Quoin Pharmaceuticals, Ltd. filed an 8-K on October 31, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The co
• Quoin Pharmaceuticals Files 8-K on Shareholder Nominations — Sep 30, 2024 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on September 30, 2024, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11 and other events. The
• Quoin Pharmaceuticals Files 8-K on Financials — Aug 14, 2024 Risk: low
  Quoin Pharmaceuticals Ltd. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition as of August 8, 2024. The filing incl
• Quoin Pharmaceuticals Faces Delisting Concerns — May 3, 2024 Risk: high
  Quoin Pharmaceuticals, Ltd. filed an 8-K on May 3, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company was formerl
• Quoin Pharmaceuticals Files 8-K on Shareholder Vote Matters — Apr 9, 2024 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on April 9, 2024, reporting on matters submitted to a vote of security holders as of April 5, 2024. The filing indicate
• Quoin Pharmaceuticals Files 8-K on Financials — Mar 13, 2024 Risk: low
  Quoin Pharmaceuticals, Ltd. filed an 8-K on March 13, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and
• Quoin Pharmaceuticals Files 8-K — Mar 8, 2024 Risk: medium
  Quoin Pharmaceuticals, Ltd. filed an 8-K on March 8, 2024, reporting on events that occurred on March 4, 2024. The filing indicates the entry into a material de
• Quoin Pharmaceuticals to Acquire VaxNewMo — Mar 6, 2024 Risk: medium
  Quoin Pharmaceuticals, Ltd. announced on February 29, 2024, that it has entered into a binding agreement to acquire all outstanding shares of the privately held
• Quoin Pharma Sells Unregistered Equity, Dilution Risk Looms — Jan 30, 2024
  On January 25, 2024, Quoin Pharmaceuticals, Ltd. entered into a material definitive agreement for an unregistered sale of equity securities. This means the comp

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX